Drug Profile
Research programme: psychiatric thereapeutics - BioMed X/ Boehringer Ingelheim
Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator BioMed X; Boehringer Ingelheim
- Class Behavioural disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psychiatric disorders
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in Psychiatric-disorders in Germany
- 11 Dec 2020 Psychiatric therapeutics are still in research trials for Psychiatric disorders in Germany
- 28 Dec 2019 No recent reports of development identified for research development in Psychiatric-disorders in Germany